Arecor Therapeutics plc
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Arecor Therapeutics plc
Intas and Arecor have struck an exclusive licensing deal that will see the pair use Arecor’s proprietary Arestat formulation technology to develop value-added medicines, in particular for use outside of the hospital setting.
A new UK company, Poolbeg Pharma, has been set up to develop new anti-infectives in an efficient manner, and already has a repositioned MAP kinase inhibitor for the treatment of severe influenza ready for Phase II studies.
Revealed: In Vivo’s list of 30 Rising Leaders across the biopharma, medtech and health technology sectors. Find out who is in the spotlight this year.
Sarah Howell, one of In Vivo’s 2021 Rising Leaders, was appointed CEO of Arecor in 2015 and has led the company’s transformation into a successful clinical-stage biotechnology company. In an exclusive interview, Howell described Arecor as focused on “affordable innovation,” particularly in disease areas with large and growing patient populations, such as diabetes.
- Controlled Release
- Drug Delivery